It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).
It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).
Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).
Rituximab probably leads to lower relapses at 6 months compared with placebo or control (moderate certainty).
Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).
Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).
Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).
The review found no eligible studies for this question.
Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).
Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).
It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.